Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults
Latest Information Update: 15 Jan 2024
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; CH 505 NP (Primary) ; Monophosphoryl lipid A; QS 21
- Indications HIV infections
- Focus Adverse reactions
- 15 Jan 2024 New trial record